Ep 56: What’s the buzz around GLP-1s and cancer with Samantha Murrell and Rob Swanda, PhD?

The Metabolic Blueprint: Weighing the Evidence on GLP-1s and Cancer Survival In this highly anticipated episode of Cracking Cancer, host Dr. Kyle Concannon sits down with patient advocate Samantha Murrell and science communicator Rob Swanda, PhD, to tackle the most talked-about presentation from the 2026 American Society of Clinical Oncology (ASCO) annual meeting: the intersection of GLP-1 receptor agonists (e.g., Ozempic, Wegovy, Mounjaro) and oncology. Samantha reveals that she has been using an off-label microdose of a GLP-1 alongside her targeted therapy for Stage IV HER2-mutant lung cancer, not for weight loss, but to target systemic, chronic inflammation. The trio breaks down large-scale real-world data tracking over 25,000 patients, which uncovered a striking associative signal: patients taking GLP-1s alongside traditional targeted therapies were twice as likely to be alive at five years compared to matched cohorts. Dr. Kyle and Rob dissect what this means from a biochemical perspective. They separate mere association from actual causation, explore why chronic inflammation can act as a shield for tumors, and detail the strict clinical rules patients must follow—such as preserving lean muscle mass to prevent cachexia—if they choose to discuss these metabolically active compounds with their oncology teams. Key Takeaways: 🟢The Staggering ASCO Survival Signal 🟢Chronic Inflammation vs. Acute Immune Response 🟢The Metformin Connection 🟢The Critical Muscle Mass Warning 🟢The "Healthy Baseline" Confounder Want to get more involved with cancer research and support the podcast? Visit the link below: ⬇️ (All proceeds go strictly towards furthering cancer research and supporting this podcast) Giving.CU.EDU/CrackingCancer  Chapters: 00:00 Sugar Feeds Cancer 01:57 Why GLP-1s Are Buzzing 05:15 Association vs Causation 07:06 Patient Concerns and Anecdotes 10:54 Inflammation Theory and ASCO Data 15:22 Evidence Review and Metformin Link 21:12 Glucose Control Mythbusting 28:00 What GLP-1 Drugs Are 30:36 Next Gen GLP-1s 31:31 Long Acting and Oral Options 32:07 ASCO Lung Cancer Signal 36:23 Interpreting Retrospective Data 39:13 Why Samantha Tried It 40:14 Absorption Theory and Dosing 41:28 Early Side Effects and Adaptation 43:01 Microdosing Caveats 45:14 Autoimmune and Histamine Effects 50:55 Broader Cancer Survival Data 53:35 Practical Safety Guidance 56:34 What We Still Dont Know To find out more about supporting the show and research endeavors, please go to the following website: www.crackingcancer.org Attributions The music track - Progression Pulse - is provided by Denys Brodovskyi through the Attribution 4.0 International License X: (1) Cracking Cancer Podcast (@Cracking_Cancer) / X IG: Cracking Cancer (@crackingcancerpodcast) • Instagram photos and videos